NCCN 2020 Congress Series™: Breast Cancer with Updates from 2019 San Antonio Breast Cancer Symposium

Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies.

Recorded Presentation from the NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of HER-2 Positive Breast Cancer
It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.
NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of HER-2 Positive Breast Cancer
It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer
Triple-negative breast cancer is an aggressive subtype that is associated with poor outcomes. Staying up-to-date on current and emerging treatment options is important to integrate new evidence-based data into their clinical practice and optimize patient outcomes.
PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing

The goal of this activity is to improve participants' knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer

Management of Metastatic Triple Negative Disease

NCCN Harmonized Guidelines™ for Sub-Saharan Africa

Clinicians around the world use NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a standard for clinical decision-making.  The NCCN Harmonized Guidelines™ are targeted regional resources created as part of a collaborative effort to combat the skyrocketing cancer rate

Challenges with the 8th Edition of the AJCC Staging Manual - Staging of Breast Cancer

As research on clinical cancer care rapidly evolves, utilizing and implementing a staging system that is primarily based on prognostic information may have limitations.

NCCN Guidelines® Updates: Breast Cancer - Multigene Testing in Breast Cancer

Numerous multigene-based assays have been developed to better prognosticate the risk of recurrence and death and predict benefit of therapy.

Pages

Subscribe to RSS - Breast Cancer